Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31273452 | 0.76 | TYMP (0.38) | TYMPKDM4EPDE9A | |
| SCHEMBL20360605 | 0.75 | CDK5 (0.40) | CDK5CDK5R1KDM4EPDE9A | |
| SCHEMBL27041198 | 0.74 | HPRT1 (0.40) | TYMPKDM4EPDE9A | |
| SCHEMBL27041171 | 0.74 | HPRT1 (0.40) | TYMPKDM4EPDE9A | |
| SCHEMBL27041175 | 0.74 | HPRT1 (0.40) | TYMPKDM4EPDE9A | |
| SCHEMBL19493361 | 0.74 | TYMP (0.48) | TYMPKDM4E | |
| SCHEMBL19493439 | 0.74 | TYMP (0.48) | TYMPKDM4E | |
| SCHEMBL31273672 | 0.73 | KDM4E (0.39) | TYMPKDM4EPDE9A | |
| SCHEMBL20481728 | 0.72 | TYMP (0.49) | TYMPKDM4E | |
| SCHEMBL25377613 | 0.72 | TYMP (0.42) | TYMPCDK5CDK5R1KDM4EPDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170296655-A1 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170296655-A1 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | CGAS, PDE11A, MAVS | TYMP 688/4885CDK5 2351/4885CDK5R1 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.